Why Monitor Kidney Function and Potassium in Heart Failure?
At a Glance
Kidney function and potassium are monitored during heart failure treatment because ACE inhibitors, ARBs, ARNIs, MRAs, and diuretics can change kidney filtration and potassium levels. Regular blood tests help clinicians adjust doses safely; an abnormal result does not always mean kidney damage.
Heart failure medications are a combination of therapies that relieve fluid overload, reduce strain on the heart, and improve long-term outcomes [1]. However, we monitor your blood work closely because these same medicines change how your kidneys filter blood and handle essential electrolytes like potassium and sodium. Regular blood tests help detect changes early, ensuring that your treatment is adjusted safely without causing severe chemical imbalances.
An abnormal lab result does not automatically mean your kidneys are permanently damaged or that the treatment has failed; testing is simply a routine tool to help your doctor find the right dose for your body.
How Your Medications Change Kidney Function and Potassium
Heart failure treatment often involves multiple medications that interact with your kidneys in different ways. Your doctor monitors your creatinine (a blood marker used to estimate your overall kidney filtration rate, known as eGFR) and electrolytes like potassium.
- ACE Inhibitors, ARBs, and ARNIs: Medications like lisinopril, losartan, or sacubitril/valsartan relax blood vessels to lower blood pressure and take stress off the heart [2]. While doing this, they change the blood flow inside your kidneys. A modest increase in your creatinine level is a common, expected effect [3]. However, they also cause your body to retain potassium [4]. (Note: ACE inhibitors, ARBs, and ARNIs are alternatives to each other. They should never be taken together, and switching between them requires specific instructions from your doctor).
- Mineralocorticoid Receptor Antagonists (MRAs): Drugs like spironolactone and eplerenone are powerful tools for improving survival, but they specifically cause your kidneys to hold on to potassium [5]. Combining them with an ACE inhibitor, ARB, or ARNI further increases the risk of high potassium (hyperkalemia) [6].
- Diuretics (Water Pills): Loop diuretics like furosemide or torsemide force your kidneys to flush out excess fluid and sodium [7]. As fluid is removed, you also lose potassium and magnesium in your urine, which can lead to low levels [8]. If diuretics remove fluid too quickly, it can lead to dehydration and stress the kidneys, causing your creatinine to rise [9].
| Medication Class | Example Drugs | Common Effect on Potassium | Typical Monitoring Focus |
|---|---|---|---|
| ACE Inhibitors / ARBs / ARNIs | Lisinopril, Losartan, Entresto | May increase potassium | eGFR, creatinine, potassium within 1-2 weeks of starting or changing dose [3] |
| MRAs | Spironolactone, Eplerenone | May increase potassium | eGFR, potassium (often within 3-7 days of starting or changing dose) [3] |
| Loop Diuretics | Furosemide, Torsemide | May decrease potassium | Kidney function, sodium, potassium, magnesium, and fluid status [7] |
The Testing Schedule: What to Expect
Because underlying kidney disease or abnormal potassium levels can alter the safety of your medications, your care team relies on a structured testing approach:
- Baseline Testing: Before starting a new medication, your doctor checks your baseline eGFR and potassium to ensure it is safe [10]. For example, MRAs usually require an eGFR above 30 and potassium below 5.0 mEq/L before starting [5].
- Follow-Up Testing: You will need repeat blood work shortly after starting a drug or changing a dose. The exact timing depends on the drug, your kidney function, and your individual risk. MRA monitoring may occur within 3 days to 1 week, while ACE inhibitors might be checked in 1 to 2 weeks [3]. Always get your blood drawn on the exact date your care team provides.
- Routine Surveillance: Once on a stable dose, you will still need regular monitoring [11].
What Happens If Your Results Are Abnormal?
Your doctor is looking for trends in your lab work to guide your care. They balance the need to protect your kidneys with keeping your heart failure treated.
- Changes prompt assessment, not automatic stops: A temporary increase in creatinine during successful fluid removal doesn’t necessarily mean permanent kidney injury [12]. Even a creatinine rise of up to 30% when starting an ACE inhibitor, ARB, or ARNI can be an acceptable response [3]. These numbers are decision points for your doctor to assess your fluid status and blood pressure, not universal rules to stop treatment [13].
- When action is needed: If your creatinine rises sharply or your potassium levels reach certain thresholds (like 5.5 mEq/L or higher), your doctor will take action [14]. They may adjust a dose, temporarily pause the drug, prescribe a medication to help remove excess potassium, or refer you to a kidney specialist [15][16]. Never stop or adjust your heart failure medications on your own based on a lab result.
Warning Signs and Everyday Safety
- Watch for Emergency Symptoms: High potassium often has no symptoms at all. However, if you experience new palpitations, severe weakness, fainting, or chest pain, seek emergency medical care immediately. If you have severe dizziness or drastically reduced urination, contact your care team promptly.
- Avoid Hidden Potassium and Kidney Stressors: Because of the risk of hyperkalemia, never take over-the-counter potassium supplements or use potassium-based salt substitutes (often marketed as “low sodium” salt) unless explicitly prescribed [17][18].
- Beware of NSAIDs and Sick Days: Over-the-counter pain relievers like ibuprofen and naproxen (NSAIDs) can severely stress your kidneys and worsen heart failure [19]. Additionally, vomiting, diarrhea, or poor fluid intake can lead to dangerous dehydration. Always ask your care team for guidance on “sick day” rules rather than stopping medications yourself [3].
Common questions in this guide
Why are kidney function and potassium checked when I take heart failure medicine?
Which heart failure medicines can make potassium too high or too low?
Is a rise in creatinine after starting heart failure medicine always dangerous?
When will I need blood tests after starting or changing a heart failure medicine?
What should I avoid while my potassium and kidney function are being monitored?
What symptoms need urgent help during heart failure medicine monitoring?
One line in your results can change your plan.
A sharp creatinine rise or high potassium on lab work can lead your doctor to adjust a dose or pause a drug. We check your results against the latest research to help you prepare for what’s next.
Related questions
Show more
Get notified when new evidence is published on congestive heart failure.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Identifying the patient with heart failure to be treated with vericiguat.
Escobar Cervantes C, Esteban Fernández A, Recio Mayoral A, et al.
Current medical research and opinion 2023; (39(5)):661-669 doi:10.1080/03007995.2023.2189857.
PMID: 36897009 - 2
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Liu RC
American journal of cardiovascular drugs : drugs, devices, and other interventions 2018; (18(6)):473-482 doi:10.1007/s40256-018-0280-5.
PMID: 29850980 - 3
Change in renal function associated with drug treatment in heart failure: national guidance.
Clark AL, Kalra PR, Petrie MC, et al.
Heart (British Cardiac Society) 2019; (105(12)):904-910 doi:10.1136/heartjnl-2018-314158.
PMID: 31118203 - 4
Treatment of Hyperkalemia in Heart Failure.
DeFilippis EM, Desai AS
Current heart failure reports 2017; (14(4)):266-274 doi:10.1007/s11897-017-0341-0.
PMID: 28656517 - 5
Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
Mares A, Rodriguez T, Deoker A, et al.
Current vascular pharmacology 2022; (20(1)):46-51 doi:10.2174/1570161119666210720120439.
PMID: 34303331 - 6
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS, Vardeny O, Claggett B, et al.
JAMA cardiology 2017; (2(1)):79-85 doi:10.1001/jamacardio.2016.4733.
PMID: 27842179 - 7
Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al.
Journal of the American Heart Association 2018; (7(18)):e009149 doi:10.1161/JAHA.118.009149.
PMID: 30371181 - 8
Hyponatremia in acute decompensated heart failure: depletion versus dilution.
Verbrugge FH, Steels P, Grieten L, et al.
Journal of the American College of Cardiology 2015; (65(5)):480-92.
PMID: 25660927 - 9
Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians.
Wu L, Rodriguez M, El Hachem K, Krittanawong C
Journal of clinical medicine 2024; (13(15)) doi:10.3390/jcm13154470.
PMID: 39124738 - 10
Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
Parikh RV, Nash DM, Brimble KS, et al.
Circulation. Cardiovascular quality and outcomes 2020; (13(9)):e006415 doi:10.1161/CIRCOUTCOMES.119.006415.
PMID: 32873054 - 11
New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J, Caballero R, Delpón E
Cardiovascular drugs and therapy 2018; (32(1)):99-119 doi:10.1007/s10557-017-6767-5.
PMID: 29372448 - 12
Acute kidney injury in acute heart failure-when to worry and when not to worry?
Banerjee D, Ali MA, Wang AY, Jha V
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (40(1)):10-18 doi:10.1093/ndt/gfae146.
PMID: 38944413 - 13
Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.
Collard D, Brouwer TF, Peters RJG, et al.
Hypertension (Dallas, Tex. : 1979) 2018; (72(6)):1337-1344 doi:10.1161/HYPERTENSIONAHA.118.11944.
PMID: 30571235 - 14
Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
Flatt DM, Brown MC, Mizeracki AM, et al.
JAMA cardiology 2016; (1(5)):607-12 doi:10.1001/jamacardio.2016.1878.
PMID: 27434136 - 15
Chronic hyperkalemia, diagnosis and management. Colombian consensus.
Rico-Fontalvo J, Rodríguez-González MJ, Yama EY, et al.
Archivos de cardiologia de Mexico 2023; (93(Supl)):1-12 doi:10.24875/ACM.23000160.
PMID: 37913795 - 16
Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use.
Clark KAA, Victoria-Castro AM, Ghazi L, et al.
JACC. Heart failure 2024; (12(2)):322-332 doi:10.1016/j.jchf.2023.08.025.
PMID: 37943221 - 17
New options for the management of chronic hyperkalemia.
Fried L, Kovesdy CP, Palmer BF
Kidney international supplements 2017; (7(3)):164-170 doi:10.1016/j.kisu.2017.09.001.
PMID: 30675431 - 18
Management of Hyperkalemia in Heart Failure.
Altay H, Çavuşoğlu Y, Çelik A, et al.
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2021; (49(Supp1)):1-32 doi:10.5543/tkda.2021.S1.
PMID: 34738907 - 19
Community prescribing of potentially nephrotoxic drugs and risk of acute kidney injury requiring renal replacement therapy in critically ill adults: A national cohort study.
Tominey S, Timmins A, Lee R, et al.
Journal of the Intensive Care Society 2021; (22(2)):102-110 doi:10.1177/1751143719900099.
PMID: 34025749
This page explains why kidney function and potassium are monitored during heart failure treatment for informational purposes only and does not constitute medical advice. Your heart failure team should interpret your results and advise you about medicines, diet, and illness-related changes.